| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6c8d4a9e0620e69c1553f6280c2a0f58 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-322 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-438
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-538
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5415 |
| filingDate |
2019-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c67d557ec41ca04bd643e46a0fc3ac4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f04ea03ff2842f056d343326549d5dc6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63ca220aee820268cc5d9863dab464c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfac83731b056bcce4b1db2bacb07011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c37b5a049b8ab1c88f3216b195ea2548
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bdcb46f467a3cf9d3a6acb8dbc614e06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09ba597d32c01ea003ec3878fdab3e2f |
| publicationDate |
2020-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-102081785-B1 |
| titleOfInvention |
Pharmaceutical composition for treatment of neurodegenerative brain disease comprising rifamycin or pharmacurically acceptable salt thereof as an active ingredient |
| abstract |
Novel pharmaceutical compositions and methods are provided for inhibiting amyloid aggregation and / or degradation, and / or inhibiting tau degradation and / or tau phosphorylation, and / or preventing and / or treating degenerative brain diseases. |
| priorityDate |
2018-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |